Sanofi invests €300 million in new Belgian biologics site
April 19, 2016Manufacturing and Production Belgium, Sanofi, belgian, flanders, geel, investment, manufacturing, pipeline
Sanofi has announced plans to expand its site in Geel, Belgium, with a €300 million investment to support its pipeline …
FDA rejects Chiasma’s new drug application for therapy to treat rare growth disorder
April 18, 2016Research and Development, Sales and Marketing Chiasma Inc, US FDA, drug trial, rare disease
Shares in Chiasma Inc (Nasdaq: CHMA) plunged to more than halve on the Nasdaq Monday as the company reported the …
Novo unveils new research grant to mark World Haemophilia Day
April 18, 2016Medical Communications, Research and Development, Sales and Marketing Novo Nordisk, grant, haemophilia, hero, world haemophilia day
Novo Nordisk has marked World Haemophilia Day 2016 with the announcement of a new research grant aimed at supporting and …
British Biosimilars Association launches in UK
April 18, 2016Manufacturing and Production, Research and Development, Sales and Marketing ABPI, Napp, bba, bgma, british biosimilars association
A new industry body, the British Biosimilars Association, has been formally launched today with the sole focus of increasing the …
Weekly Movers: Valeant, Depomed, Intercept Pharma, Insys Therapeutics and more…
April 18, 2016Manufacturing and Production, Research and Development, Sales and Marketing Depomed, Intercept Pharma, Relypsa, Share price, Stock Movement, Valeant, stock market
Troubles don’t seem to go away for Canada-based Valeant Pharma (NYSE: VRX) with news of a probable sale doing the …
Sticking the boot in
April 18, 2016Sales and Marketing Boots, Cost, Guardian, NHS, prescribing, scandal, unfair
A recent exposé has shone a light on the practices allegedly enforced at the nation’s largest pharmacy. So what exactly …
Sosei‘s Heptares And Kymab to collaborate on developing new antibody therapeutics
April 18, 2016Research and Development, Sales and Marketing Heptares Therapeutics, Kymab Ltd, Sosei Group, collaboration, drug development, immuno-oncology
Japan’s Sosei Group Corp (TSE: 4565) has signed a collaboration deal with Kymab Ltd to develop and market novel antibody …
Roche sues Intas Pharma over patent dispute in India
April 18, 2016Medical Communications, Sales and Marketing India, Roche, anaemia, chronic kidney, intas, intas pharmaceuticals, patent
Roche Pharmaceuticals is suing Indian-based Intas Pharmaceuticals, alleging that the company has infringed upon its patent rights to anaemia drug, …
NICE recommends PTC Therapeutics’ Translarna to treat Duchenne muscular dystrophy
April 18, 2016Sales and Marketing DMD, Duchenne Muscular Dystrophy, NICE, PTC Therapeutics, Translarna, regulation
Shares in drug maker PTC Therapeutics (Nasdaq: PTCT) jumped after the National Institute for Health and Care Excellence (NICE) backed …
Shire announces new $400 million biologics plant and 400 new jobs in Ireland
April 18, 2016Manufacturing and Production, Sales and Marketing IDA, Ireland, Shire, investment, meath, shire pharmaceuticals
Shire Pharmaceuticals has announced the expansion of its Irish operations with a new $400 million biologics plant set to deliver …
AstraZeneca hold internal talks for Medivation takeover – reports
April 18, 2016Manufacturing and Production, Sales and Marketing 7 billion, AstraZeneca, Medivation, Sanofi, jp morgan, merger, takeover
AstraZeneca (LSE: AZN) is said to have held initial internal talks concerning a potential £7 billion offer for US drug …
Clinical trial initiated to help Paris attacks victims with PTSD
April 15, 2016Medical Communications, Research and Development France, clinical trial, mcgill, mcgill university, terror attacks
Victims of the recent Paris terror attacks have been offered the opportunity to take part in a clinical trial, organised …
Gilead Sciences says Phase III trials for chronic HBV drug meet primary endpoints
April 15, 2016Gilead Sciences, US FDA, chronic hepatitis B, drug trial
Biotech firm Gilead Sciences (NYSE: GILD) on Friday announced positive results from late-stage trials for its drug to treat chronic …
Repros Therapeutics says positive results from Phase II trial of uterine fibroids drug; shares jump
April 15, 2016Medical Communications, Research and Development Repros Therapeutics, Shares, US FDA, drug trial, uterine fibroids
Shares in Repros Therapeutics (Nasdaq: RPRX) surged to close over 18% Thursday after the company announced positive mid-stage trial results …
Pfizer fined for epilepsy drug price increase by UK antitrust regulator
April 15, 2016Medical Communications CMA, Flynn Pharma, Pfizer, antitrust, competition and markets authority, epilepsy, fine, flynn
Pfizer has been fined for unfairly increasing the price of epilepsy drug Epanutin (phenytoin sodium) by the UK Competition and …
US annual spending on drugs rose 12.2% in 2015 – IMS
April 15, 2016Medical Communications, Research and Development, Sales and Marketing IMS Health, drug spending
The total US spending on prescription drugs rose 12.2% to almost $425 billion in 2015 on the back of new …
Roche’s cholesterol-lowering drug candidate shows promise in fighting prostate cancer
April 15, 2016Medical Communications, Research and Development RO 48-9071, Roche, cholesterol, drug, missouri, oncology, university
Researchers from the University of Missouri have found that a compound developed by Roche Pharmaceuticals for the treatment of high …
Synta Pharmaceuticals announces merger with Madrigal
April 15, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Phase II, Synta, madrigal, merger
Synta Pharmaceuticals (NASDAQ: SNTA) has announced a definitive merger agreement with Madrigal Pharmaceuticals under which the newly-formed company will focus …
Merck appoints Maya Martinez-Davis as global head of oncology
April 14, 2016Medical Communications Merck, maya martinez-davis, oncology
Merck has announced the appointment of Maya Martinez-Davis as the new global head of oncology at the German-based company. In …
Merck says US FDA to review its Keytruda for head & neck cancer
April 14, 2016Research and Development, Sales and Marketing Cancer Immunotherapy, Merck & Co, US FDA, keytruda
The US Food and Drug Administration has accepted Merck & Co’s (NYSE: MRK) supplemental biologics license application (sBLA) for its immunotherapy cancer …
Latest content
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations
